Panitumumab-IRDye800 for Brain Cancer

This trial tests the safety and imaging capabilities of a new fluorescent agent, panitumumab-IRDye800, in patients with brain lesions scheduled for surgical removal. The treatment involves administering a single dose of the agent before surgery to enhance tumor visibility. Participants are divided into two groups: one receiving a 50 mg dose and the other a 100 mg dose. Eligible candidates have brain lesions requiring surgery and may have undergone previous chemotherapy or radiation. As an Early Phase 1 trial, this research aims to understand how the treatment works in people, offering participants the opportunity to be among the first to receive this innovative approach.

Research has shown that panitumumab-IRDye800 is generally safe for patients with brain tumors. In one study involving 11 patients, researchers found no harmful side effects. Another study confirmed that this treatment helps surgeons see tumor cells more clearly and is safe at doses of 50 mg and 100 mg. These findings suggest that the treatment is well-tolerated and effective in improving tumor visibility during surgery.¹²³⁴⁵

Most treatments for brain cancer involve surgery, radiation, and chemotherapy. However, Panitumumab-IRDye800 is unique because it uses a fluorescent dye combined with an antibody to help surgeons see cancer cells more clearly during surgery. This approach aims to improve the precision of tumor removal, potentially leading to better outcomes for patients. By enhancing visualization, this treatment could reduce the likelihood of cancer cells being left behind, which is a common challenge with current surgical methods. Researchers are excited about this treatment as it represents a novel way to aid surgical procedures and possibly improve survival rates for brain cancer patients.

Research has shown that panitumumab-IRDye800 is a special dye that enhances tumor visibility during surgery. It targets a protein called EGFR, often abundant on certain cancer cells. Early studies demonstrated that this dye can make cancerous tissues more visible, potentially aiding surgeons in more effective tumor removal. In this trial, participants will receive either a 50 mg or 100 mg dose of panitumumab-IRDye800 before their standard-of-care neurosurgical resection. In trials with other cancers, such as pancreatic cancer, panitumumab-IRDye800 improved tumor visibility for surgeons. Its safety has been well-documented, making it a promising tool for surgeries involving brain tumors.⁶⁷⁸⁹¹⁰